All News

Intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in resected stage IIB-IV melanoma.

Previous research shows that in newly diagnosed AML, CR and composite remission rates were higher for shortened regimens of venetoclax.

Waist circumference (WC) predicts mortality risk in older adults independent of BMI, with high WC linked to 24% greater death risk, a new study finds.

A secondary analysis of the HELIOS-B trial found that worse left atrial strain was associated with higher risks of mortality and cardiovascular events.

Heidi Overton, MD, PhD, a physician and White House health policy aide, would replace acting commissioner Kyle Diamantas, JD.

Frequent adolescent sexual assault and discrimination in employment, housing, and police interactions was associated with higher heart failure risk.

Low fruit and vegetable intake alongside high sodium consumption remain top dietary drivers of CKD burden, with disparities by region, age, and income.

Experts discuss why patients with HFmrEF/HFpEF still receive less urgent, less standardized care than those with reduced ejection fraction.

Previous research has tied the loosening of permit-to-purchase and concealed carry laws to increased firearm suicide rates.

Fecal immunochemical tests (FITs) generate substantially fewer emissions than colonoscopy or CT colonography, driven largely by transportation.

COVID wastewater levels are climbing again in the Bay Area. Here's what to know about XFG "Stratus," Nimbus, symptoms, and vaccine protection.

At an AJMC roundtable, Atlanta clinicians detailed blood-based biomarker gaps, uncompensated care, and capacity strains slowing Alzheimer diagnosis.

The increasingly complex CLL treatment landscape will require continued real-world study to guide sequencing decisions.

An expert discusses gaps in pediatric alopecia areata evidence, missed trial outcomes, and what managed care should change for children with the disease.

The third-gen PCKS9 inhibitor was approved in December 2025 as adjunctive treatment alongside diet and exercise for adults with hypercholesterolemia.

Arshad Khanani, MD, weighs Wnt- and Tie2-targeting agents against gene therapy and makes the case for payers to look past price to long-term value.

Roundtable reveals vitiligo care gaps: Opzelura leads, insurers still call it cosmetic, and pricey oral JAKs near approval—what’s next?

A gene tied to poor sarcoma prognosis also rose fastest in pazopanib-sensitive sarcoma cell lines, a new exploratory study suggests.

A national survey finds retina specialists tolerate higher GA treatment risks in exchange for greater lesion growth rate reduction.

Most eligible people with multiple sclerosis have never used GLP-1 receptor agonists, despite their potential cardiometabolic benefits.

New hypertension drugs cost over $800,000 per QALY vs generics, well above cost-effectiveness limits, ICER's draft report finds.

This meta-analysis encompassed 18 studies published through December 31, 2025.

Eli Lilly's investigational triple agonist is already fueling gray-market sales and a $1 trillion valuation narrative ahead of its 2027 FDA filing.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

A foundation model built on routine sleep studies outperformed the apnea-hypopnea index (AHI) in predicting mortality and cardiovascular risk in patients with sleep apnea.

Genetic ancestry was linked to differences in colorectal cancer (CRC) burden and age-specific risk, with implications for screening.

The cereblon E3 ligase modulator, or CELMoD, also received a breakthrough therapy designation from the FDA.

Rising premiums and out-of-pocket costs top Americans' health care concerns across party lines, a Commonwealth Fund survey finds.